Hematech, LLC
Records under this name other than patents Hematech, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Hematech, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,429,690 | Transgenic bovines having reduced prion protein production Formerly held Term ended Term ended Jul 30, 2024 · From the USPTO record | Term ended | Term ended Jul 30, 2024 | From the USPTO record |
| US 7,491,534 | Methods for altering cell fate to generate T-cells specific for an antigen of interest Formerly held Term ended Term ended Mar 29, 2024 · From the USPTO record | Term ended | Term ended Mar 29, 2024 | From the USPTO record |
| US 7,652,192 | Cloning of transgenic unglulates comprising artificial chromosomes Formerly held Term ended Term ended Jun 7, 2023 · From the USPTO record | Term ended | Term ended Jun 7, 2023 | From the USPTO record |
| US 7,253,334 | Methods for cloning non-human mammals using reprogrammed donor chromatin or donor cells Formerly held Term ended Term ended Jan 29, 2023 · From the USPTO record | Term ended | Term ended Jan 29, 2023 | From the USPTO record |
| US 7,491,867 | Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates Formerly held Term ended Term ended Feb 9, 2021 · From the USPTO record | Term ended | Term ended Feb 9, 2021 | From the USPTO record |
| US 7,074,983 | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin Formerly held Term ended Term ended Jan 24, 2021 · From the USPTO record | Term ended | Term ended Jan 24, 2021 | From the USPTO record |
| US 7,736,895 | Methods for altering cell fate Formerly held Lapsed on the fee record Ended Jun 15, 2014 · From the USPTO record | Lapsed on the fee record | Ended Jun 15, 2014 | From the USPTO record |
| US 7,420,099 | Transgenic animals and uses thereof Formerly held Lapsed on the fee record Ended Sep 2, 2012 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2012 | From the USPTO record |
| US 7,414,170 | Transgenic bovines capable of human antibody production Formerly held Lapsed on the fee record Ended Aug 19, 2012 · From the USPTO record | Lapsed on the fee record | Ended Aug 19, 2012 | From the USPTO record |
| US 4,064,118 | Blood substitute based on hemoglobin Term ended Term ended no later than Dec 20, 1997 · Low confidence | Term ended | Term ended no later than Dec 20, 1997 | Low confidence |